SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT00242840

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

A 24 Week Phase IIIb/IV Single Arm Open Label Observational Study to Explore the Efficacy of Protease Inhibitors Given in Combination With Reverse Transcriptase Inhibitors to HIV-1 Infected Subjects With Protease Mutations Selected During Therapy With GW433908 Containing Antiretroviral Therapy

This study will assess the efficacy of subsequent protease inhibitor (PI)-containing therapy in subjects who have acquired HIV-1 protease mutations whilst receiving a GW433908 (fosamprenavir)-containing regimen.

NCT00242840 Infection, Human Immunodeficiency Virus I HIV Infection
MeSH:Infection Communicable Diseases HIV Infections Acquired Immunodeficiency Syndrome

1 Interventions

Name: No intervention; Observational study

Type: Drug



There are 9 SNPs

SNPs


1 D30N

Exclusion criteria: - Have 2 or more of the primary resistance mutations D30N, G48V, V82A/F/T/S and L90M. --- D30N ---


2 G48V

Exclusion criteria: - Have 2 or more of the primary resistance mutations D30N, G48V, V82A/F/T/S and L90M. --- D30N --- --- G48V ---


3 I47V

- Must be failing virologically (>1000 copies at two consecutive time-points) and have a screening genotype with evidence of at least one new APV-associated protease mutation: V32I (+/- I47V), I50V, I54L/M, I84V acquired since commencing treatment with GW433908. --- V32I --- --- I47V ---


4 I50V

- Must be failing virologically (>1000 copies at two consecutive time-points) and have a screening genotype with evidence of at least one new APV-associated protease mutation: V32I (+/- I47V), I50V, I54L/M, I84V acquired since commencing treatment with GW433908. --- V32I --- --- I47V --- --- I50V ---


5 I54L

- Must be failing virologically (>1000 copies at two consecutive time-points) and have a screening genotype with evidence of at least one new APV-associated protease mutation: V32I (+/- I47V), I50V, I54L/M, I84V acquired since commencing treatment with GW433908. --- V32I --- --- I47V --- --- I50V --- --- I54L ---


6 I84V

- Must be failing virologically (>1000 copies at two consecutive time-points) and have a screening genotype with evidence of at least one new APV-associated protease mutation: V32I (+/- I47V), I50V, I54L/M, I84V acquired since commencing treatment with GW433908. --- V32I --- --- I47V --- --- I50V --- --- I54L --- --- I84V ---


7 L90M

Exclusion criteria: - Have 2 or more of the primary resistance mutations D30N, G48V, V82A/F/T/S and L90M. --- D30N --- --- G48V --- --- V82A --- --- L90M ---


8 V32I

- Must be failing virologically (>1000 copies at two consecutive time-points) and have a screening genotype with evidence of at least one new APV-associated protease mutation: V32I (+/- I47V), I50V, I54L/M, I84V acquired since commencing treatment with GW433908. --- V32I ---


9 V82A

Exclusion criteria: - Have 2 or more of the primary resistance mutations D30N, G48V, V82A/F/T/S and L90M. --- D30N --- --- G48V --- --- V82A ---



HPO Nodes